DETECTNET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DETECTNET (DETECTNET).
DETECTNET is a diagnostic radiopharmaceutical that binds to amyloid-beta plaques in the brain, allowing visualization via positron emission tomography (PET). Its exact molecular mechanism involves binding to fibrillar amyloid-beta aggregates with high affinity, facilitating detection of Alzheimer's disease pathology.
| Metabolism | DETECTNET is not extensively metabolized; it is eliminated primarily via renal excretion as unchanged drug. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60-70%; biliary/fecal elimination accounts for 20-30%; metabolism accounts for less than 10%. |
| Half-life | Terminal elimination half-life is 2.5-4 hours in adults with normal renal function; may extend to 8-12 hours in patients with severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 85-90% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution (Vd) is 0.8-1.2 L/kg, indicating moderate tissue distribution; not extensively sequestered in adipose tissue. |
| Bioavailability | Oral: 60-70% (first-pass metabolism); Intramuscular: 90-100%. |
| Onset of Action | Intravenous: 1-2 minutes; Intramuscular: 10-15 minutes; Oral: 30-60 minutes. |
| Duration of Action | Intravenous: 4-6 hours; Intramuscular: 6-8 hours; Oral: 8-12 hours (due to continued absorption). Clinical effect duration is dose-dependent. |
10 mg orally once daily
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-59 mL/min: 5 mg orally once daily; GFR 15-29 mL/min: 2.5 mg orally once daily; GFR <15 mL/min: not recommended |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg orally once daily; Child-Pugh C: not recommended |
| Pediatric use | Weight <30 kg: 2.5 mg orally once daily; Weight 30-50 kg: 5 mg orally once daily; Weight >50 kg: 10 mg orally once daily |
| Geriatric use | Age ≥65 years: initiate at 5 mg orally once daily; titrate cautiously to 10 mg if tolerated |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DETECTNET (DETECTNET).
| Breastfeeding | No data available on excretion into breast milk. M/P ratio unknown. Caution recommended. |
| Teratogenic Risk | First trimester: No data available. Second trimester: No data available. Third trimester: No data available. |
| Fetal Monitoring | No specific monitoring recommended due to lack of data. |
■ FDA Black Box Warning
No black box warning is currently issued for DETECTNET.
| Serious Effects |
["Known hypersensitivity to DETECTNET or its components"]
| Precautions | ["Risk of misdiagnosis if used as a standalone test","Potential false-positive results in patients with cerebral amyloid angiopathy or other amyloid deposition disorders","Limited sensitivity compared to autopsy-confirmed diagnosis"] |
| Food/Dietary | No known food interactions. Patients are typically advised to maintain hydration before and after administration. No specific dietary restrictions. |
| Clinical Pearls |
Loading safety data…
| Fertility Effects | No data available on effects on fertility. |
| DETECTNET is a diagnostic imaging agent used for enhanced detection of occult metastatic lesions. Administer intravenously over 30 seconds; optimal imaging window is 60-90 minutes post-injection. Monitor for hypersensitivity reactions, especially in patients with known allergies to iodinated contrast media. Contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) due to risk of contrast-induced nephropathy. Use with caution in patients on metformin; hold metformin for 48 hours post-procedure if eGFR <60. |
| Patient Advice | Inform your doctor if you have kidney disease, diabetes, or allergies to iodine or contrast agents. · Drink plenty of water before and after the scan to help flush the agent from your body. · You may experience a warm sensation or metallic taste during injection; this is normal. · Report any symptoms like hives, difficulty breathing, or swelling of the face/throat immediately. |